Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells.

Cells - 21 Dec 2019

Lorenzon Ilaria, Pellarin Ilenia, Pellizzari Ilenia, D'Andrea Sara, Belletti Barbara, Sonego Maura, Baldassarre Gustavo, Schiappacassi Monica

Abstract excerpt

Platinum-based chemotherapy is the therapy of choice for epithelial ovarian cancer (EOC). Acquired resistance to platinum (PT) is a frequent event that leads to disease progression and predicts poor prognosis. To understand possible mechanisms underlying acquired PT-resistance, we have recently generated and characterized three PT-resistant isogenic EOC cell lines. Here, we more deeply characterize several...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial
Share to Cell Cycle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Drug Resistance, Neoplasm

Share to Mitosis

Share to Ovarian Neoplasms

Share to Platinum

Source

Open in PubMed Open full text

Identifiers

PMID: 31877751
DOI: 10.3390/cells9010036
PMCID: PMC7016977

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells.PMID 31877751Read ↗

Ovarian Cancer—Insights into Platinum Resistance and Overcoming ItSemantic proximity Read ↗

Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells.Semantic proximity Read ↗

p53-R248W evades doxorubicin mediated cell death through collective alteration in TOP2A and CYP1A1 genes in cancer cells.Semantic proximity Read ↗

Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer.Semantic proximity Read ↗

The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs.Semantic proximity Read ↗

Gold(iii) complexes inhibit growth of cisplatin-resistant ovarian cancer in association with upregulation of proapoptotic PMS2 geneSemantic proximity Read ↗

A kinetically inert platinum antitumor agent overcomes mutant p53-driven chemoresistance via oxidative stress-mediated DNA damage.Semantic proximity Read ↗

Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.Semantic proximity Read ↗

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedinSemantic proximity Read ↗

Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating AgentsSemantic proximity Read ↗

Novel monofunctional platinum (II) complex Mono-Pt induces apoptosis-independent autophagic cell death in human ovarian carcinoma cells, distinct from cisplatinSemantic proximity Read ↗

Generation of Cisplatin-Resistant Ovarian Cancer Cell LinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.